SynthesisHaematologica2021
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients.
Synthesis in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Effect of daratumumab on patients with high-risk cytogenetic multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2026Pooled it
- Pooled it
- International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Guideline
- Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.Blood cancer journal · 2024Pooled it
- Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.Blood cancer journal · 2024Trial
- Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.Blood cancer journal · 2024Trial
- Trial
- Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma.Leukemia · 2026Article
- Next-generation sequencing-based high-risk genomic stratification in multiple myeloma.Translational cancer research · 2026Article
- Long-term prognostic impact of chromosome 1 abnormalities in newly diagnosed multiple myeloma patients: a monocentric study.Annals of hematology · 2026Article
- Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib-Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis.Current oncology (Toronto, Ont.) · 2026Article
- Article
- MASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma.Annals of medicine · 2025Article
- Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders.Leukemia · 2025Review
- The past, present, and future of myeloma staging and risk prognostication.The oncologist · 2025Review
- Article
- Temporal genomic dynamics shape clinical trajectory in multiple myeloma.Nature genetics · 2025Article
- Article
- A Single-Center Study on Frontline Treatment for Multiple Myeloma Patients With 1q Abnormalities.EJHaem · 2025Article
- Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma.Blood neoplasia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.